<img height="1" width="1" src="https://www.facebook.com/tr?id=200201724533423&amp;ev=PageView &amp;noscript=1">
Contact Us

    GENOMIND PRESS ROOM

    September 10, 2020

    Genomind Announces Major Industry-Leading HLA-A Test Innovation on its Comprehensive Mental Health Pharmacogenetics (PGx) Test, Increasing Utility for Tens of Thousands of Clinicians and Patients

    Summary:

    New patent-pending, real-time polymerase chain reaction (PCR) technique can accurately detect the human leukocyte antigen HLA-A*31:01 genetic variant, reducing the 40% false positive rate associated with the industry testing approach. Genomind’s® Professional PGx Express™ is now the only mental health pharmacogenetics (PGx) test using this capability in the market. Given the recent positive coverage decisions by major health insurers, Genomind will be leading national education efforts to make this innovation widely available to clinicians and patients

    Continue Reading...
    June 24, 2020

    Genomind Releases Mental Health Map Consumer DNA Test

    A breakthrough in the translation of genetic mechanisms and traits that can influence a person’s behavioral predispositions, Genomind Mental Health Map provides the starting point to empower consumers to take action towards better mental health and wellness
    Continue Reading...
    April 23, 2020

    Genomind Coordinates With Multiple Health Plans to Expand Access to Its Pharmacogenetics Tools and Help Reduce Mental Health-Related ER and Hospital Visits During the COVID-19 Crisis

    Demand for mental health tools and services skyrockets; SAMSHA crisis hotline reported 9 times the number of requests for mental health crisis support in March

    Continue Reading...
    April 16, 2020

    Webinar - How HCPs can shift to telepsychiatry

    In this new era, thousands of mental health professionals are looking for ways to stay engaged with patients and run their practice during the COVID-19 outbreak. To help you navigate this transition, Genomind offers an  on-demand webinar that includes a panel of experts, hosted by our own Chief Medical Officer Dr. David Krause.  Learn how to transition your practice to telepsychiatry, gain insights into the regulatory landscape, and how to continue to use Genomind’s Pharmacogenetic testing from home.

    Continue Reading...
    March 25, 2020

    Helping You Shift to Telepsychiatry in the Era of COVID-19

    Recent government actions enable telepsychiatry

    Continue Reading...
    March 19, 2020

    Genomind Launches Express Ship-to-Patient Capability for Genomind Professional PGx Express Test Enabling Access to Critical Mental Health Treatment Information

    As the first company to offer direct-to-patient, at-home mental health pharmacogenetic testing, Genomind is helping patients and physicians gain actionable mental health insights without having to leave their homes

    Continue Reading...

    SEARCH NEWS